bluebird bio(BLUE) Stock Price Today | Quotes & News

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

BLUE bluebird bio

Watchlist

3.750
-0.100-2.60%

Close Mar 26 16:00 ET

3.770
+0.020+0.53%

Post 19:05 ET

36.53MMarket Cap-0.10P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
BenzingaMar 11 10:17 ET
Earnings Week Ahead: TGT, COST, CRWD, AVGO, JD, PLUG, MRVL, and More
Seeking AlphaMar 2 08:00 ET
Bluebird Bio Price Target Cut to $5.00/Share From $40.00 by Wells Fargo
Dow JonesFeb 24 13:21 ET · Ratings
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Dow JonesFeb 24 13:21 ET · Ratings
Bluebird Bio Stock Slides for Second Day on Buyout News
Seeking AlphaFeb 24 11:55 ET
Baird Downgrades Bluebird Bio(BLUE.US) to Hold Rating, Cuts Target Price to $5
Moomoo NewsFeb 24 08:31 ET · Ratings

Comments

Jaguar8

Mar 21 20:24

Filing

$bluebird bio (BLUE.US)$
bluebird bio has entered into a definitive agreement to be acquired by Carlyle and SK Capital in a deal valuing the company at up to $9.84 per share. Shareholders will receive $3.00 per share in cash plus a contingent value right of $6.84 per share, payable if the company achieves $600 million in net sales within a specified period ending December 31, 2027.
The transaction comes after bluebird's comprehensive strategic review involving over 70 potential investors, ...

102315509

Feb 22 02:45

$bluebird bio (BLUE.US)$ bounce back a little bit more please

SteadyBoomBeepBeep

Feb 21 22:30

$bluebird bio (BLUE.US)$ easy, rebound

Jaguar8

Feb 21 20:55

NEWS

$bluebird bio (BLUE.US)$
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Friday, 21st February at 7:30 am
bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions
bluebird's Board of Directors determined this transaction is in the best interest of stockholders following a comprehensive review of strategic alternatives
...